James Marken - ANI Pharmaceuticals VP Devel
| BSFA Stock | 51.00 0.00 0.00% |
Insider
James Marken is VP Devel of ANI Pharmaceuticals
| Age | 60 |
| Phone | 218 634 3500 |
| Web | https://www.anipharmaceuticals.com |
James Marken Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Marken against ANI Pharmaceuticals stock is an integral part of due diligence when investing in ANI Pharmaceuticals. James Marken insider activity provides valuable insight into whether ANI Pharmaceuticals is net buyers or sellers over its current business cycle. Note, ANI Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell ANI Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Marken over six months ago Disposition of 7250 shares by James Marken of ANI Pharmaceuticals at 49.51 subject to Rule 16b-3 | ||
James Marken over six months ago Disposition of 5300 shares by James Marken of ANI Pharmaceuticals at 57.06 subject to Rule 16b-3 | ||
James Marken over six months ago Disposition of 3653 shares by James Marken of ANI Pharmaceuticals at 69.58 subject to Rule 16b-3 |
ANI Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0374) % which means that it has lost $0.0374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2567) %, meaning that it generated substantial loss on money invested by shareholders. ANI Pharmaceuticals' management efficiency ratios could be used to measure how well ANI Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Matthias Evers | Evotec SE | 50 | |
| Volker Braun | Evotec SE | N/A | |
| Anja Bosler | Evotec SE | N/A | |
| Monika Conradt | Evotec SE | N/A | |
| Dirk Toepfer | Merck KGaA | N/A | |
| Matthias Heinzel | Merck KGaA | 56 | |
| Gerhard Schmitz | Merck KGaA | 60 | |
| Friederike Rotsch | Merck KGaA | 51 | |
| Marcus Kuhnert | Merck KGaA | 55 | |
| Karin Samusch | Dermapharm Holding SE | N/A | |
| MBA MBA | Evotec SE | 54 | |
| Andreas Eberhorn | Dermapharm Holding SE | 48 | |
| Constantin Fest | Merck KGaA | 46 | |
| Enno Spillner | Evotec SE | 53 | |
| Christof Dreibholz | Dermapharm Holding SE | 56 | |
| Gabriele Hansen | Evotec SE | N/A | |
| Britta Hamberger | Dermapharm Holding SE | N/A | |
| HansGeorge Feldmeier | Dermapharm Holding SE | N/A | |
| Belen MD | Merck KGaA | 63 | |
| Kai Beckmann | Merck KGaA | 58 | |
| Craig Johnstone | Evotec SE | 53 | |
Management Performance
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0374 |
ANI Pharmaceuticals Leadership Team
Elected by the shareholders, the ANI Pharmaceuticals' board of directors comprises two types of representatives: ANI Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ANI. The board's role is to monitor ANI Pharmaceuticals' management team and ensure that shareholders' interests are well served. ANI Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ANI Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nikhil Lalwani, CEO Pres | ||
| Meredith Cook, Gen VP | ||
| Chad Gassert, Sr Strategy | ||
| Elizabeth JD, Chief Disease | ||
| James Marken, VP Devel | ||
| Ori Gutwerg, VP Generics | ||
| Stephen Carey, Sr CFO | ||
| Krista Davis, Chief Officer | ||
| Muthusamy RPh, COO RD | ||
| Christopher Mutz, Head Disease |
ANI Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ANI Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | |||
| Return On Asset | -0.0374 | |||
| Profit Margin | (0.24) % | |||
| Operating Margin | (0.13) % | |||
| Current Valuation | 894.88 M | |||
| Shares Outstanding | 17.45 M | |||
| Shares Owned By Insiders | 13.11 % | |||
| Shares Owned By Institutions | 75.34 % | |||
| Price To Book | 2.16 X | |||
| Price To Sales | 2.23 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.